These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Histopathology and clinical course of chronic, myeloproliferative diseases]. Georgii A Verh Dtsch Ges Pathol; 1983; 67():214-34. PubMed ID: 6666265 [No Abstract] [Full Text] [Related]
11. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308 [TBL] [Abstract][Full Text] [Related]
12. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)]. Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769 [No Abstract] [Full Text] [Related]
13. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Phekoo KJ; Richards MA; Møller H; Schey SA; Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393 [TBL] [Abstract][Full Text] [Related]
14. Complications and conversions in myeloproliferative disorders: an analysis of 356 cases. Wang Y; Zuo A; Liu Y; Liu B; Hao C; Wang L; Zhou X; Qian L Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):314-7. PubMed ID: 12411064 [TBL] [Abstract][Full Text] [Related]
15. [Indices of cellular and humoral immunity in chronic myeloproliferative diseases]. Vygovskaia IaI; Loginskiĭ VE; Mazurok AA; Shnitsar ZV Ter Arkh; 1986; 58(9):93-6. PubMed ID: 3491438 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM; Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462 [TBL] [Abstract][Full Text] [Related]
17. [Unusual case of chronic myeloproliferative syndrome]. Tosato F; Fossaluzza V Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999 [TBL] [Abstract][Full Text] [Related]
18. [So-called primary (idiopathic) osteomyelofibrosis/-sclerosis (OMF) within the scope of chronic myeloproliferative diseases. II. Course and therapy in 102 patients with special reference to early hyperplastic and advanced fibrosclerotic stages]. Zankovich R; Thiele J; Mödder B; Steinberg T; Simon KG; Fischer R; Diehl V Med Klin (Munich); 1988 Oct; 83(19):629-36. PubMed ID: 3185421 [No Abstract] [Full Text] [Related]
19. [Isolation of size-dependent human platelet subpopulations. I. The method for isolation of size-dependent platelet subpopulations by counterflow centrifugal elutriation]. Saigo K; Ryo R; Nakaya Y; Yamaguchi N; Ryo R; Saigo K; Ueda K Rinsho Byori; 1986 Oct; 34(10):1159-62. PubMed ID: 3807001 [No Abstract] [Full Text] [Related]
20. ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders. Moreno MJ; Lozano ML; Ferrer F; Bellosillo B; Besses C; Vicente V; Martínez C Blood Coagul Fibrinolysis; 2009 Jul; 20(5):390-2. PubMed ID: 19542939 [No Abstract] [Full Text] [Related] [Next] [New Search]